Search | Clinical Trials Finder

Conditions: Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions; Biological
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Euglycemia, Hypoglycemia, Hyperglycemia
Interventions: Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pre Diabetes, Insulin Resistance, Diabetes Mellitus, Type 2
Interventions: Dietary, Oral Food Challege; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Coagulopathy, Hemorrhage
Interventions: Autologous Spray Dried Plasma; Combination Product
Lead sponsor: Velico Medical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin

Conditions: Non Small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more

Conditions: Asthma, Allergies
Interventions: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging); Biological · Procedure
Lead sponsor: Andrew D. Luster, M.D.,Ph.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII, ITI; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more

Conditions: Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions: ARC1779 Injection, Placebo (normal saline); Drug
Lead sponsor: Archemix Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Hackensack, New Jersey • Houston, Texas

Conditions: Covid19
Interventions: Selenium (as Selenious Acid), Placebo; Drug · Other
Lead sponsor: CHRISTUS Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Longview, Texas

Conditions: Healthy
Interventions: [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Anesthesia
Interventions: Not listed
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years to 89 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Male Infertility, Nonobstructive Azoospermia, Azoospermia
Interventions: Platelet rich plasma; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: ICU
Interventions: ceftobiprole q12h, ceftobiprole q8h; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Chicago, Illinois • Beech Grove, Indiana + 1 more

Conditions: Infertility of Uterine Origin
Interventions: Platelet Rich Plasma Intrauterine infusion, Normal saline Intrauterine infusion; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: System; Lupus Erythematosus
Interventions: Low Dose Mesenchymal Stem Cells (MSCs); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Charleston, South Carolina

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Alzheimer's Disease
Interventions: Albumin 5%, Albumin 20%, Immunoglobulin; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 22
States / cities: Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more

Conditions: Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions: Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: 18-NaF PET, DCE-MRI, 18-FDG PET/CT; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes
Interventions: Muscle Biopsy, Jell-O with Amino acids, Dextrose; Procedure · Other · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

Intravenous Exenatide (Byetta) During Surgery

Precision Diets for Diabetes Prevention

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

T Cell Effector and Regulatory Mechanisms in Asthma

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion

Platelet Rich Plasma Testis Treatment for Infertile Men

Neural Mechanism of Aldosterone-induced Insulin Resistance

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

Platelet Rich Plasma for Insufficient Endometrium

Control of Major Bleeding After Trauma Study

Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Autologous Transplant To End NMO Spectrum Disorder

Imaging in MGUS, SMM and MM

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus